

THERAPEUTIC ASSETS

Therapeutic Asset Name	Indication	Product Format	MOA	Faculty or Institute	Partnered or Available	Discovery	Hit to lead	Lead optimisation	Pre-clinical	Clinical	Sales
Oncology											
Gardasil	Cervical cancer	Vac	HPV VLPs	UQMed	CSL, Merck						
C3aR	Variety of tumours	SM and Bio	Stimulates an immune response	UQMed/AIBN	Partnered						
Q-202	Breast cancer	SM	CRAC inhibitor	HABS	Available-C						
BARF-1	EBV+ lymphoma, gastric and nasopharyngeal cancer	Bio	ADCC and CDC	UQMed	Available-B						
Combination therapy for enhanced ADCC	Cancers treated with targeted antibody therapies	SM	Dynamin inhibition	UQMed	Available-T						
Immunotherapy	Personalised tumour vaccine	LF	Dendritic cell targeted nanoparticle	UQMed	Available-T						
NUR77 / NR4A1	Breast cancer	SM	Nuclear hormone receptor inhibitor	IMB	Available-S						
MYB	AML, rare adenoid cystic carcinoma, colon and ER+ve breast	SM	Inhibitor of MYB-p300 interaction	UQMed / HABS	Available-T						
SOX18 inhibitor	Solid tumour metastasis	SM	Sox18 inhibitor	IMB	Available-S						
Pain											
EMA401	Neuropathic	SM	AT ₂ antagonist	HABS	Spinifex, Novartis						
ORL-1 modulator	Nociceptive	Pep	ORL-1 agonist	IMB	Available-S						
Enogesia	Painful diabetic neuropathy	SM	Novel furoxan nitric oxide (NO) donors	HABS / MABS	Available-B						
IMB007	Visceral	Pep	GABA B agonist	UQMed / IMB	Available-S						
Nav1.7	Acute and chronic	Pep	Nav1.7 antagonist	IMB	Available-S						
GlyR	Inflammatory	SM	α3 GlyR potentiator	IMB / QBI	Available-S						
Inflammation and Autoimmune											
DEN-181	Rheumatoid arthritis	LF	Tolerising immunotherapy	UQMed	Dendright, Janssen						
Inflammasome inhibitor	Inflammation	SM	NLRP3 inhibitor	IMB	Inflazome						
PGD2	Asthma and allergic rhinitis	SM	PGD2 synthase inhibitor	IMB	Available-S						
PAR2 modulator	Inflammation (IBD, Psoriasis)	SM	PAR2 antagonist	IMB	Available-S						
C3a modulator	Inflammation (arthritis, asthma and IBD)	SM	C3a receptor antagonist	IMB	Available-S						
Neurestore	Inflammation (sepsis & ischaemia-reperfusion injury)	Bio	EphA4 antagonist	UQMed/QBI	Available-S						
Novel compounds	Inflammation (IBD, arthritis)	SM	Undisclosed target	IMB	Available-S						
C5a	Inflammation (arthritis, IBD, lupus, neuroinflammation)	Pep	C5a receptor antagonist	UQMed	Available-S						
Tolerising immunotherapy	Autoimmune diseases, MS and celiac disease	LF	Antigen specific immune tolerance induction	UQMed	Available-C						
NASH, Diabetes and Obesity											
FGF1 obesity	Obesity	Bio	Antisense inhibition of FGFR	Mater-UQ	Verva, Ionis Pharma						
PAR2 modulator	Obesity and type 2 diabetes	SM	PAR2 antagonist	IMB	Available-S						
Targeted IL-22	NASH and type 2 diabetes	Bio	IL-22 modulator	Mater-UQ	Available-B						
CNS											
Neurestore	Amyotrophic lateral sclerosis and spinal cord injury	Bio	EphA4 antagonist	QBI	NuNerve						
Triheptanoin	Epilepsy	OF	Triheptanoin	UQSc	UltraGenyx						
Nav1.1	Epilepsy	Pep	Nav1.1 agonist	IMB	Available - S						
Novel compounds	Alzheimer's and Parkinson's disease	SM	Acetylcholinesterase inhibitor	HABS	Available-B						
ASIC1a	Stroke neuroprotection and cardiac myoprotection	Pep	Selective ASIC1a inhibitor	IMB	Available-S						
Infectious Diseases											
Ebola vaccine	Post exposure prophylaxis for Ebola virus	Vac	Glycoprotein-specific equine IgG	UQSc	Available-G						
Vancaptcin	MDR Gram positive bacteria	Pep	Membrane disruption	IMB	Available-T						
Novel octapeptin and polymyxin analogues	MDR Gram negative bacteria	Pep	Membrane disruption	IMB	Available-T						
Antibiotic RESTART	Hospital acquired MDR Gram negative bacteria	SM	Adjuvant to restore killing effect of existing antibiotics	UQSc	Available-T						
Antibacterial drug candidates	Urinary tract infection, tuberculosis and malaria	SM	PRTase inhibitor	UQSc	Available-G						
Molecular clamp sub-unit vaccine	Broad-spectrum flu, RSV, ebola and others	Vac	Hyper-stabilised viral pre-fusion protein	UQSc	Available-C						
Insect specific flavivirus vaccines	Yellow Fever, Dengue, Zika, West Nile and other flaviviruses	Vac	Chimeric flavivirus with insect-specific flavivirus	UQSc	Available-G						

CELL BASED ASSETS

Therapeutic Asset Name	Indication	Product Format	MOA	Faculty or Institute	Partnered or Available	Discovery	Pre-clinical	Clinical	Sales
Regenerative Medicine and Cell Therapies									
TheraPhil	Neutropenia	CT	Neutrophils	AIBN	CCRM				
Endothelial progenitor cell based treatment	Critical limb ischaemia and other vascular conditions	CT	Stem cells	UQMed	Available-B				
Kidney tissue from iPSCs	Kidney tissue for therapeutic use in direct surgical applications	CT	Stem cells	IMB	Available-C				
Porous tissue scaffold	Tissue scaffold	Material	Method to control porosity	AIBN	Available-G				
Scaffold that mimicks cell surface	Tissue scaffold or implant coating	Material	Controlled spacing of polymer surface features	AIBN	Available-G				

Asset Name	Description/Field	Faculty or Institute	Partnered or Available	POC validated	Prototype	Lead product	Sales
Research and Development Tools							
Conditions optimiser	Device to optimise stem cell culturing conditions	AIBN	US Start-up				
Kidney organoids from iPSCs	Kidney tissue for drug discovery and toxicology screening	IMB	Organovo Inc				
Growth hormone assay	in vitro bioassay for growth hormone and analogues	IMB	Available-S				
Release media	Enables culturing of difficult stem cells	AIBN	Available-C				

BIOTECH ASSETS

Asset Name	Description/Field	Faculty or Institute	Partnered or Available	POC validated	Prototype	Lead product	Sales
Biomedical Devices and Diagnostic Technologies							
ImpediMed	Lymphoedema bioimpedance	UQSc	ImpediMed				
ResApp	Mobile health for respiratory disease diagnosis	EAIT	ResApp Health				
Q-Sera	Universal pathology blood clotting tube	UQMed	Q-Sera				
SMART Arm	Device which helps stroke survivors regain arm function faster	HABS	SMART Arm				
Protease biosensor	Rapid detection of functional proteases	IMB	Molecular Warehouse				
Brain scanning ultrasound	Scanning ultrasound for treating Alzheimer's Disease	QBI	Available-B				
Faceted optical fibre tips	Laser radiation with wide divergence for odontology applications	HABS	Available-B				
Rapid nucleic acid extraction	Method for extraction of amplification-ready nucleic acids from crude tissue samples in just 30 seconds	UQSc	Available-C				
Flavivirus diagnostics	Assay with highly specific antigens to detect of a range of flaviviruses	UQSc	Available-G				
PLA-Dx Breast cancer prognostic	Prognostic to identify HR+ breast cancer likely to recur in patients with aromatase therapy	Mater-UQ	Available-T				
Vaccine and Drug Delivery Platforms							
Nanopatch	Needle-free vaccine delivery	AIBN	Vaxxas				
ProGel	Oral stable to small intestine	UQSc	ProGel				
Nano-emulsions	Tailored stable emulsions with targeting capability	AIBN	Optioned to partner				
Pepfactants	Controllable peptide surfactant	AIBN	Optioned to partner				
Caveospheres	Membrane enclosed vesicles	IMB	Available-S				
VLP vaccine platform	Fast, scalable and adjuvant free virus-like particles	AIBN	Some fields available-G				
Bi-specific antibody	Multi-specific targeting constructs for immunotherapy, imaging and sample purification	AIBN	Available-B				
Nanocapsules	Encapsulated emulsion droplets for sustained or burst release and ability to coat microbes	AIBN	Available-G				
Peptide adjuvant	Self-assembling adjuvant for peptide vaccines	UQMed	Available-G				
Nasal spray delivery for insoluble drugs	Liquid formulation which gels upon contact with nasal membrane to extend drug absorption	HABS	Available-B				
Healthcare Assessment Programs							
Nursing assessment software	In-hospital patient assessment software for nurses	UQMed	RAISoft				
CeGa Online	Acute care remote	UQMed	Available-B				
GAI	Geriatric anxiety inventory via eShop	HSS	Available-A				
Emergency Department Screener	Workflow software for emergency admissions	UQMed	Available-B				
CHAP	Health assessment tool via eShop	UQMed	Available-A				

UQ Faculties and Institutes

AIBN Australian Institute for Bioengineering & Nanotechnology
IMB Institute for Molecular Bioscience | **Mater-UQ** Mater Research Institute-UQ **QBI** Queensland Brain Institute | **UQ** The University of Queensland | **HABS** Faculty of Health and Behavioural Sciences
UQSc Faculty of Science | **UQMed** Faculty of Medicine | **HSS** Faculty of Humanities and Social Sciences | **EAIT** Faculty of Engineering, Architecture and Information Technology

Product Format

Bio Biologic
CT Cell therapy
LF Liposome formulation
OF Oil-based formulation
PEP Peptide
R Reformulation
SM Small molecule
Vac Vaccine

CONTACT US

Available-C Dr Craig Belcher Senior Director, Commercial Engagement - Life Sciences
Available-A Ms Anne Bannister Senior Director, Commercial Engagement - Social and Behavioural Sciences
Available-B Dr Ben Phillis Director, Commercial Engagement - Medical Devices & Drug Delivery
Available-G Dr George Adamson Director, Commercial Engagement - Science
Available-S Dr Stephen Earl Director, Commercial Engagement - Therapeutics
Available-T Dr Tamsin Terry Director, Commercial Engagement - Lifesciences

c.belcher@uniquet.com.au +61 407 637 853
a.bannister@uniquet.com.au +61 409 736 292
b.phillis@uniquet.com.au +61 407 375 695
g.adamson@uniquet.com.au +61 402 284 340
s.earl@uniquet.com.au +61 421 780 689
t.terry@uniquet.com.au +61 409 156 555